Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
dc.contributor.author | McLellan, JS | |
dc.contributor.author | Pancera, M | |
dc.contributor.author | Carrico, C | |
dc.contributor.author | Gorman, J | |
dc.contributor.author | Julien, JP | |
dc.contributor.author | Khayat, R | |
dc.contributor.author | Louder, R | |
dc.contributor.author | Pejchal, R | |
dc.contributor.author | Sastry, M | |
dc.contributor.author | Dai, K | |
dc.contributor.author | O'Dell, S | |
dc.contributor.author | Patel, N | |
dc.contributor.author | Shahzad ul Hussan, S | |
dc.contributor.author | Yang, Y | |
dc.contributor.author | Zhang, B | |
dc.contributor.author | Zhou, T | |
dc.contributor.author | Zhu, J | |
dc.contributor.author | Boyington, JC | |
dc.contributor.author | Chuang, GY | |
dc.contributor.author | Diwanji, D | |
dc.contributor.author | Georgiev, I | |
dc.contributor.author | Kwon, YD | |
dc.contributor.author | Lee, D | |
dc.contributor.author | Louder, MK | |
dc.contributor.author | Moquin, S | |
dc.contributor.author | Schmidt, SD | |
dc.contributor.author | Yang, ZY | |
dc.contributor.author | Bonsignori, M | |
dc.contributor.author | Crump, JA | |
dc.contributor.author | Kapiga, SH | |
dc.contributor.author | Sam, NE | |
dc.contributor.author | Haynes, BF | |
dc.contributor.author | Burton, DR | |
dc.contributor.author | Koff, WC | |
dc.contributor.author | Walker, LM | |
dc.contributor.author | Phogat, S | |
dc.contributor.author | Wyatt, R | |
dc.contributor.author | Orwenyo, J | |
dc.contributor.author | Wang, LX | |
dc.contributor.author | Arthos, J | |
dc.contributor.author | Bewley, CA | |
dc.contributor.author | Mascola, JR | |
dc.contributor.author | Nabel, GJ | |
dc.contributor.author | Schief, WR | |
dc.contributor.author | Ward, AB | |
dc.contributor.author | Wilson, IA | |
dc.contributor.author | Kwong, PD | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2017-03-02T19:25:40Z | |
dc.date.available | 2017-03-02T19:25:40Z | |
dc.date.issued | 2011-11-23 | |
dc.description.abstract | Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand. | |
dc.identifier | ||
dc.identifier | nature10696 | |
dc.identifier.eissn | 1476-4687 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Nature | |
dc.relation.isversionof | 10.1038/nature10696 | |
dc.subject | AIDS Vaccines | |
dc.subject | Amino Acid Motifs | |
dc.subject | Amino Acid Sequence | |
dc.subject | Antibodies, Neutralizing | |
dc.subject | Antibody Affinity | |
dc.subject | Antibody Specificity | |
dc.subject | Antigen-Antibody Complex | |
dc.subject | Binding Sites, Antibody | |
dc.subject | Conserved Sequence | |
dc.subject | Crystallography, X-Ray | |
dc.subject | Epitopes | |
dc.subject | Glycopeptides | |
dc.subject | Glycosylation | |
dc.subject | HIV Antibodies | |
dc.subject | HIV Envelope Protein gp120 | |
dc.subject | HIV-1 | |
dc.subject | Hydrogen Bonding | |
dc.subject | Immune Evasion | |
dc.subject | Models, Molecular | |
dc.subject | Molecular Sequence Data | |
dc.subject | Polysaccharides | |
dc.subject | Protein Structure, Quaternary | |
dc.subject | Protein Structure, Tertiary | |
dc.title | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. | |
dc.type | Journal article | |
duke.contributor.orcid | Bonsignori, M|0000-0003-2973-2101 | |
duke.contributor.orcid | Crump, JA|0000-0002-4529-102X | |
pubs.author-url | ||
pubs.begin-page | 336 | |
pubs.end-page | 343 | |
pubs.issue | 7377 | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Duke Human Vaccine Institute | |
pubs.organisational-group | Global Health Institute | |
pubs.organisational-group | Immunology | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
pubs.organisational-group | Medicine, Infectious Diseases | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | University Institutes and Centers | |
pubs.publication-status | Published online | |
pubs.volume | 480 |
Files
Original bundle
- Name:
- Nature_gp120V1V2Structure.pdf
- Size:
- 2.4 MB
- Format:
- Adobe Portable Document Format